Poolbeg Pharma plc presents pre-clinical study data

9 December 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces key insights from its poster presentation at the 66th American Society of Hematology ('ASH') Annual Meeting and Exposition, San Diego, California.

The poster, which detailed POLB 001 as a promising preventative therapy for Cytokine Release Syndrome (CRS) associated with cancer immunotherapies, was presented by the Company’s Chief Executive Officer, Jeremy Skillington, PhD on Saturday 7 December.

The study was designed to evaluate the effect of POLB 001 on CRS compared to Adalimumab, an anti-TNF antibody which is a gold standard potent inhibitor of CRS in humanised tumour-bearing mouse models. Mice were treated twice daily with either placebo or POLB 001 at low, medium, or high doses for five days.

Mark Sumeray, MD, Consultant Clinical Advisor for Poolbeg, commented: 

Addressing cancer immunotherapy-induced CRS holds the potential to greatly impact the treatment of hematological malignancies – enhancing safety and reaching more patients. These data presented at ASH are promising, demonstrating statistically significant cytokine inhibition and a dose dependent reduction in clinical CRS. The results of this animal study support development of POLB 001 in a Phase 2 clinical study as a prophylactic for the prevention of immunotherapy-induced CRS. The previous successful LPS trial in healthy human volunteers also provides ratification.